RUNX2: A Potential Drug Target and Biomarker for Runx Transcription Factor 2

Target Name: RUNX2

NCBI ID: G860

RUNX2

RUNX2: A Potential Drug Target and Biomarker for Runx Transcription Factor 2

RUNX2, also known as Runt-related transcription factor 2 (ISOform B), is a non-coding RNA molecule that plays a crucial role in regulating gene expression in various organisms, including humans. It is a key transcription factor that is expressed in various tissues and organs, including the brain, heart, and gastrointestinal tract. RUNX2 has been shown to be involved in a wide range of physiological processes, including cell proliferation, differentiation, and survival.

The RUNX2 gene was first identified in the late 1990s by researchers who were studying the regulation of gene expression in various organisms. Since then, numerous studies have demonstrated that RUNX2 plays a critical role in the regulation of gene expression, particularly in the development and maintenance of tissues and organs.

One of the most significant functions of RUNX2 is its ability to promote the expression of target genes. RUNX2 has been shown to physically interact with various DNA-binding proteins, including the DNA-binding domain of the transcription factor ASXL1. This interaction allows RUNX2 to physically pull the ASXL1 protein towards its DNA target, thereby enhancing the activity of the transcription factor.

In addition to its role in gene expression, RUNX2 has also been shown to play a critical role in the regulation of cellular processes such as cell adhesion, migration, and apoptosis. Studies have shown that RUNX2 can physically interact with various cell adhesion molecules, including E-cadherin, and that this interaction is critical for the maintenance of stem cell stemness.

Another function of RUNX2 is its ability to promote the expression of genes involved in stress response. RUNX2 has been shown to play a critical role in the regulation of stress response pathways, including the unfolded-DNA response (IDR) and the double-strand break repair (DSR) pathways. These pathways are critical for the regulation of cellular stress, and RUNX2 has been shown to be involved in the regulation of genes involved in these pathways.

In addition to its role in stress response, RUNX2 has also been shown to play a critical role in the regulation of cellular processes related to cell survival. Studies have shown that RUNX2 can physically interact with various cell survival factors, including p53, and that this interaction is critical for the regulation of cellular survival.

Given the numerous functions of RUNX2, it is not surprising that it has been identified as a potential drug target. Studies have shown that RUNX2 is involved in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. In addition, RUNX2 has also been shown to be involved in various biological processes that are involved in aging, such as the regulation of cellular senescence.

In conclusion, RUNX2 is a non-coding RNA molecule that plays a critical role in regulating gene expression and cellular processes. Its functions include the promotion of gene expression, cell adhesion, migration, and apoptosis, as well as the regulation of stress response and cellular survival. Given its involvement in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases, RUNX2 is a potential drug target that could be developed as a new therapeutic agent.

Protein Name: RUNX Family Transcription Factor 2

Functions: Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis (PubMed:28505335, PubMed:28738062, PubMed:28703881). Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Inhibits KAT6B-dependent transcriptional activation

The "RUNX2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RUNX2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets